- Home
- DHIL vs PRTA Comparison
DHIL vs PRTA Comparison
Compare DHIL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHIL | PRTA |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 482.3M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DHIL | PRTA |
|---|---|---|
| Price | $172.98 | $9.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 23.7K | ★ 383.0K |
| Earning Date | 06-01-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 14.37 | N/A |
| EPS | ★ 17.91 | N/A |
| Revenue | ★ $145,201,729.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $4.32 |
| 52 Week High | $173.00 | $14.60 |
Technical Indicators
Market Signals| Indicator | DHIL | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 60.48 |
| Support Level | $170.59 | $9.54 |
| Resistance Level | $173.00 | $10.72 |
| Average True Range (ATR) | 0.74 | 0.55 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 79.05 | 85.94 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.